title: Neoadjuvant Chemotherapy Using Reduced-Dose Docetaxel Followed by Radical Prostatectomy for Patients With Intermediate and High-Risk Prostate Cancer: A Single-Center Study.
abstract: To assess safety, pathologic response rate, and long-term oncologic outcomes of radical prostatectomy (RP) after neoadjuvant chemotherapy using reduced-dose docetaxel without androgen-deprivation therapy in prostate cancer (PCa) patients of intermediate- and high-risk groups.
  
  
  
  Forty-four patients with PCa (PSA > 10 ng/ml, Gleason score 7 or more, or clinical stage cT2c or more) were included with a median follow-up of 11.4 years after RP. One group (NCT/RP) received neoadjuvant treatment 3-weekly with docetaxel (36 mg/m(2) for up to six cycles, 21 patients), the other (control) group (RP, 23 patients) received RP only.
  
  
  
  Toxicities were mild with grade 3 events not exceeding 10%. A statistically significant reduction of PSA > 50% post-chemotherapy was observed in 52.4% cases. Cancer-specific survival (CSS) was 90% in the NCT/RP group and 60.9% in the RP group (P = 0.042). The biochemical recurrence-free survival was 68.5% in the NCT/RP and 37.7% in the RP groups; overall survival was 75.5% and 54.6%, respectively (both P > 0.05).
  
  
  
  The use of neoadjuvant chemotherapy before RP in a selected regimen and dose represents a safe strategy and results in benefits in CSS. Given the limitations of the study, this concept should be evaluated in large, prospective, controlled studies. Prostate 76: 1345-1352, 2016. © 2016 Wiley Periodicals, Inc.
authors: Department of Oncological Urology, Petrov N.N. Research Institute of Oncology, Saint-Petersburg, Russia.
authors: Alexander
authors: A
authors: Nosov
authors: Department of Oncological Urology, Petrov N.N. Research Institute of Oncology, Saint-Petersburg, Russia. sgreva79@mail.ru.
authors: Sergey
authors: S
authors: Reva
authors: Department of Oncological Urology, Petrov N.N. Research Institute of Oncology, Saint-Petersburg, Russia.
authors: Sergey
authors: S
authors: Petrov
authors: Department of Oncological Urology, Petrov N.N. Research Institute of Oncology, Saint-Petersburg, Russia.
authors: Eldar
authors: E
authors: Mamijev
authors: Department of Oncological Urology, Petrov N.N. Research Institute of Oncology, Saint-Petersburg, Russia.
authors: Roman
authors: R
authors: Novikov
authors: Urology Clinic of the S.P. Botkin City Clinical Hospital, Moscow, Russia.
authors: Evgeniy
authors: E
authors: Veliev
authors: Clinic for Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany.
authors: Florian
authors: F
authors: Imkamp
authors: Clinic for Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany.|Institute of Pathology, University Hospital of Bonn, Bonn, Germany.
authors: Yuri
authors: Y
authors: Tolkach
authors: Saint-Petersburg Oncological Center, Saint-Petersburg, Russia.
authors: Vladimir
authors: V
authors: Moiseenko
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D005240:Feasibility Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D043823:Taxoids / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel
keywords: docetaxel; neoadjuvant chemotherapy; prostate cancer; radical prostatectomy; survival